|
Catalysts
Feb 17, 2016 19:55:03 GMT -5
via mobile
Post by lakers on Feb 17, 2016 19:55:03 GMT -5
Historically the break-up settlement comes ahead of the last date and final handover but there is precedence for litigation post handover. I will not go on record to any amount but just observing past deals and the dynamics of this, I remain in the 120mm - 200mm range for Sny to get a hold harmless. Realize many on the board think this way to high but they have to pay for BrandiCun*'s halt to all activity that was not planned in any way prior to this bureaucrat's appointment. We will get TS news plus SNY divorce settlement plus some regional plans to get this moving. JMHO $120M-$200M plus forgiven used LOC ~ $50M by 4/4/16 = $170M-$250M settlement is in the realm of possibility. Sanofi may forgive the used LOC so that they can close it. If that happens, Mnkd can keep ~ $23M cash after it sells the Valencia building (no lien). That's why I think Mnkd should ask for used LOC up to 4/4/16 to be forgiven. Otherwise, Sanofi may have to keep LOC open until it's used up. Furthermore, at high 8% interest, Sanofi might keep it open.
|
|
|
Post by agedhippie on Feb 17, 2016 21:13:26 GMT -5
$120M-$200M plus forgiven used LOC ~ $50M by 4/4/16 = $170M-$250M settlement is in the realm of possibility. Sanofi may forgive the used LOC so that they can close it. If that happens, Mnkd can keep ~ $23M cash after it sells the Valencia building (no lien). That's why I think Mnkd should ask for used LOC up to 4/4/16 to be forgiven. Otherwise, Sanofi may have to keep LOC open until it's used up. Furthermore, at high 8% interest, Sanofi might keep it open. The obvious question here is why? Those numbers have no rationale whereas they have to be precise for arbitration. I can see why Mannkind would want this money, but I cannot see why Sanofi who are in the middle of an austerity push are going to pay it.
|
|
|
Post by mnholdem on Feb 19, 2016 8:28:52 GMT -5
CEO Pfeffer needs to continue to portray MannKind Corporation as a company that will NOT go down without a fight:
Words can be a powerful catalyst, as illustrated in this clip from Independence Day, where the President of the United States is talking about the fate of MannKind... ummm, I mean mankind:
Matt's new directive of better communication and greater transparency must be improved upon continually, IMO.
I think that I'll replay this on April 5th.
|
|
|
Post by wmdhunt on Feb 19, 2016 12:02:27 GMT -5
The Mintaka Foundation for Medical Research
14 chemin des Aulx
1228 Plan-les-Ouates
Switzerland
Many deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.
|
|
|
Post by lakers on Feb 22, 2016 14:31:19 GMT -5
Mnkd and Sanofi are in process of resolving the (licensing) agreement, I learnt. The 4Q15 ER CC date will be on Mon 2/29/16, TBA'ed shortly.
|
|
|
Post by goyocafe on Feb 22, 2016 17:05:42 GMT -5
Mnkd and Sanofi are in process of resolving the (licensing) agreement, I learnt. The 4Q15 ER CC date will be on Mon 2/29/16, TBA'ed shortly. "resolving", i.e., "dissolving"?
|
|
|
Catalysts
Feb 22, 2016 21:28:15 GMT -5
via mobile
Post by bradleysbest on Feb 22, 2016 21:28:15 GMT -5
Hopefully they are resolving it with a cash settlement !
|
|
|
Post by yash on Feb 22, 2016 23:30:49 GMT -5
Lakers, any hint that resolving may mean SNY still interested?
|
|
|
Post by lakers on Feb 23, 2016 0:13:14 GMT -5
Hopefully they are resolving it with a cash settlement ! It means cash settlement.
|
|
|
Post by mnholdem on Feb 23, 2016 5:34:20 GMT -5
I'm hoping that Sanofi also forgives the debt, which would also dissolve the loan agreement and the accompanying rights it gives Sanofi to Afrezza patents, plant & property as collateral...although some extra cash would be a nice addition.
|
|
|
Post by kball on Feb 23, 2016 7:54:43 GMT -5
Hopefully they are resolving it with a cash settlement ! It means cash settlement.Flash to that scene of Mannkind shareholders all singing on that bus
|
|
|
Post by bradleysbest on Feb 23, 2016 14:22:04 GMT -5
If Matt comes through with what he "suggested" in the RBC conference we have some light at the end of the tunnel. Hopefully (big if) MNKD negotiates a cash settlement, a new partner is already lined up, applications for approval of Afrezza into foreign countries, a NEW TS deal are all ANNOUNCED shortly after the termination is official. It really has been a tough go for us "longs"! Hopefully 2016 is the year things get turned around.
|
|
|
Post by peppy on Feb 23, 2016 14:32:07 GMT -5
If Matt comes through with what he "suggested" in the RBC conference we have some light at the end of the tunnel. Hopefully (big if) MNKD negotiates a cash settlement, a new partner is already lined up, applications for approval of Afrezza into foreign countries, a NEW TS deal are all ANNOUNCED shortly after the termination is official. It really has been a tough go for us "longs"! Hopefully 2016 is the year things get turned around. If you want to play you have to pay. The US Food and Drug Administration (FDA) The price tag: the standard new drug filing fee of $2.4 million. FYI www.raps.org/Regulatory-Focus/News/2016/02/22/24378/Sanofi-Redeems-245M-Priority-Review-Voucher-for-Type-2-Diabetes-Treatment/#sthash.6LLx8hUO.dpuf
What does the EU charge? parity? Japan?
|
|
|
Post by kbrion77 on Feb 23, 2016 14:46:05 GMT -5
How about a simple catalyst of getting an episode of HBO's Vice, doing wonders for EYES right now.
|
|